[Therapeutic experience on the effect of thalidomidomide on lepra reaction].
D001241:Aspirin / Q000627:therapeutic use; D002980:Climate; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007557:Israel; D007918:Leprosy / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009431:Neural Conduction; D009461:Neurologic Manifestations; D010919:Placebos; D012877:Skin Manifestations; D013256:Steroids / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D014459:Ulnar Nerve / Q000503:physiopathology; D014606:Uveitis, Anterior / Q000188:drug therapy / Q000209:etiology
D010919:Placebos; D013256:Steroids; D013450:Sulfones; D013792:Thalidomide; D001241:Aspirin
Therapeutische Erfahrungen über den Einfluss des Thalidomids bei der Lepra-Reaktion